ESG professionals are navigating a highly uncertain landscape in 2025, driven by shifting regulatory pressures in the U.S. - including growing scrutiny of social and climate-related initiatives under anti-ESG federal policies. At the same time, the rollback of EU disclosure requirements for U.S. multinationals, through the Omnibus package and the ‘Stop-the-Clock’ Directive, has added further complexity.

Amid this turbulence, critical questions are emerging:

• What are the reputational and business risks of communicating around topics like DE&I?
• What does the future of ESG reporting hold and what should organizations be doing in the interim?
• How can ESG teams continue to operate effectively with leaner budgets?

Despite the challenges, there is opportunity. Those who can adapt quickly, cut through the noise, and stay ahead of regulatory shifts will be best positioned to lead the next era of ESG strategy with clarity, resilience, and impact. Now more than ever, ESG professionals in the life sciences sector must come together to benchmark against peers, align on strategic priorities, and navigate rapidly evolving regulatory landscapes - ensuring they drive meaningful progress for investors, employees, patients, and the planet.

Following the success of our Boston and European editions, the ESG in Life Sciences Summit West brought together senior leaders in ESG, Sustainability, Compliance, Procurement, Supply Chain, and Finance from across the West Coast to: